{
  "schema_version": "1.0",
  "last_updated": "2026-07-08",
  "drug": "tirzepatide",
  "titration_schedule": [
    {
      "weeks": "1-4",
      "dose_mg": 2.5,
      "note": "starting dose, for tolerability not efficacy"
    },
    {
      "weeks": "5-8",
      "dose_mg": 5.0,
      "note": "first therapeutic dose"
    },
    {
      "weeks": "9-12",
      "dose_mg": 7.5,
      "note": "increase if tolerated"
    },
    {
      "weeks": "13-16",
      "dose_mg": 10.0,
      "note": "increase if tolerated"
    },
    {
      "weeks": "17-20",
      "dose_mg": 12.5,
      "note": "increase if tolerated"
    },
    {
      "weeks": "21+",
      "dose_mg": 15.0,
      "note": "maximum maintenance dose"
    }
  ],
  "cost_implication": "On dose-tiered pricing, monthly cost typically rises with dose. Flat-rate programs hold one price across all doses.",
  "note": "Titration is individualized by a prescribing clinician. Compounded tirzepatide is not FDA-approved."
}